Skip to content

One plant. One purpose. Standard shipping free on orders over $100 worldwide.

the specialist store

Safety & evidence · read before you buy

Is Pueraria Mirifica safe? What the research shows and what it does not

A plain summary of the evidence, the limits and who should not use it.

On this page, in short

4
pieces of research, with the facts to judge them
24 wk
the longest trial we cite
—
long-term safety is not established

Short answer

Pueraria mirifica has been tested in small, short human trials. Its compounds bind estrogen receptors, so it can act like an estrogen, and long-term safety is not established. Some people should not use it, and several regulators have issued warnings.

9 sources ~6 min read Not medical advice

Please check this list first

Who should not use it

Pueraria mirifica products are often not recommended for the people below. If any of this applies to you, please speak with your doctor before using any product that contains it.

  1. Anyone who is pregnant or nursing.
  2. Anyone with a hormone-sensitive condition, or taking medicine that affects hormones.

This list follows the advice published by the Hong Kong Centre for Food Safety in March 2011.

What the research looked at

Here are four pieces of research, with the facts you need to judge them. Most of the human studies were done in postmenopausal women and looked at vaginal health, not breast skin. They help with safety questions, but they do not show what our products do.

Study 1 RCT · oral

Shinryo to Shinyaku, 2017

Design
Randomized controlled trial of Pueraria mirifica taken by mouth
Duration
12 weeks
Measured
Firmness of the skin on the upper breast, and the angle between the breast fold and the nipple

Study 2 RCT · oral

Manonai and colleagues, Menopause, 2007

Design
Randomized, double-blind, placebo-controlled trial of capsules taken once daily, at three dose levels
People
71 healthy postmenopausal women aged 45 to 60 (51 received Pueraria mirifica, 20 received placebo)
Duration
24 weeks
Measured
Vaginal symptoms, vaginal health index, vaginal pH and vaginal cell tests

Safety finding

The authors reported no significant difference in adverse effects between the Pueraria mirifica and placebo groups.

Study 3 RCT · vaginal gel

Warinsiriruk and colleagues, Maturitas, 2022

Design
Randomized, double-blinded, placebo-controlled trial of a vaginal gel (applied to the skin and tissue, not taken by mouth)
People
72 postmenopausal women with genitourinary syndrome of menopause
Duration
12 weeks
Measured
Vaginal blood flow, vaginal maturation index, vaginal health index, womb lining thickness and symptoms

Related trial

A related 2016 randomized trial (Suwanvesh and colleagues, published in Menopause in 2017) compared a Pueraria mirifica gel with a conjugated estrogen cream in 82 postmenopausal women over 12 weeks. The estrogen cream did better at improving signs of vaginal atrophy and restoring the vaginal lining at 6 and 12 weeks.

Study 4 Systematic review

Kongkaew and colleagues, Journal of Ethnopharmacology, 2018

Design
Systematic review of clinical trials (searches ran to February 2017)
People
Eight studies in 9 articles, using data from 309 menopausal women
Duration
Varied between studies
Measured
Menopausal symptoms, reproductive hormones, urinary and genital function and bone markers

Limits noted by the authors

The active ingredients and sources of Pueraria mirifica were not defined, and they called for long-term safety studies and ongoing monitoring.

What we do not know

The limits of the evidence.

How long the trials ran, on a five-year scale
  • Study 1 · oral 12 wk
  • Study 2 · oral 24 wk
  • Study 3 · gel 12 wk
  • 2016 gel vs cream 12 wk

Hatched area: time with no trial data in the research cited here.

Long-term safety
The trials above lasted 12 to 24 weeks.
Who the studies included
Most participants were postmenopausal women.
Which product was tested
The systematic review noted that the active ingredients and the plant sources were not defined across studies, so results from one product do not automatically apply to another.

Side effects reported in research

24-week trial · 71 women

Adverse effects did not differ significantly between the Pueraria mirifica groups and placebo. A second paper on the same trial found no estrogen-like effect on the womb lining and reported mild adverse effects in both the Pueraria mirifica and placebo groups.

2018 systematic review

Similar rates of breast tenderness, vaginal spotting and dizziness across the groups it looked at. It also reported that serum C-reactive protein, a marker of inflammation, doubled.

Pueraria mirifica and HRT

Pueraria mirifica is not hormone replacement therapy, and it should not be used in its place. In the 2016 trial of 82 postmenopausal women, a conjugated estrogen cream was more effective than a Pueraria mirifica gel at improving signs of vaginal atrophy. If you are considering hormone therapy, please talk with your doctor about the options.

Questions about cancer

Pueraria mirifica contains plant compounds that bind estrogen receptors. For that reason, anyone with a history of, or risk factors for, a hormone-sensitive cancer should speak with their doctor first and should not start on their own.

Choosing a product with care

Because the review noted that ingredients and sources were not defined across studies, it helps to know what is in the product you choose. Root age, the extraction method and how the extract is standardized all matter, and may matter more than the shape of the product.

What to look for

  • Where the plant was grown and how old the roots are.
  • How the extract is made.
  • Testing of each production lot.
  • Certificates from the factory that makes the product.

You can read how we handle each of these, and see our certificates, on the two pages below.

Quality and extraction Quality and certifications

Questions people ask

What are the side effects of Pueraria mirifica?

In the research above, adverse effects were reported as mild and similar to placebo in the trials we cite, but those trials were small and short. Please read the section on side effects and talk with your doctor if you have concerns.

Does it increase estrogen?

It contains plant compounds that bind to estrogen receptors, so it can act like an estrogen. It does not contain estradiol, the body's own estrogen. Responses vary from person to person, which is why some people are asked to speak with a doctor first.

Is it linked to cancer?

Please see the section on cancer above. In short, people with hormone-sensitive conditions should speak with their doctor first.

Can I ask someone before I buy?

Yes. Message a specialist on WhatsApp and ask whether a product is suitable for you. For medical questions, your doctor is the right person.

Ask a specialist on WhatsApp

There is no rush

If you decide to try it

Once you have checked the list above and spoken with your doctor if needed, these pages can help you choose where to start.

References

  1. Shinryo to Shinyaku (2017). Randomized controlled trial of oral Pueraria mirifica and breast skin firmness.
  2. Manonai J, Chittacharoen A, Theppisai U, Theppisai H. Effect of Pueraria mirifica on vaginal health. Menopause. 2007;14(5):919–924.
  3. Manonai J, Chittacharoen A, Udomsubpayakul U, Theppisai H, Theppisai U. Effects and safety of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women. Menopause. 2008.
  4. Warinsiriruk P, Tantitham C, Cherdshewasart W, Shobeiri SA, Manonai J. Effects of Pueraria mirifica on vaginal artery vascularization in postmenopausal women with genitourinary syndrome of menopause. Maturitas. 2022;160:4–10.
  5. Suwanvesh N, Manonai J, Sophonsritsuk A, Cherdshewasart W. Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women. Menopause. 2017;24:210–215.
  6. Kongkaew C, Scholfield NC, Dhippayom T, Dilokthornsakul P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Pueraria candollei var. mirifica for menopausal women: a systematic review of clinical trials and the way forward. Journal of Ethnopharmacology. 2018.
  7. Centre for Food Safety, Hong Kong. Risk in Brief: Thai kudzu (Pueraria mirifica) in breast boosting food. March 2011.
  8. NutraIngredients. Finns ban breast enhancement miracle herb. October 2009.
  9. NutraIngredients Asia. South Korea authorities detect banned Thai kudzu in imported health foods. June 2023.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Herbal supplements are not a substitute for medical advice. Talk to a healthcare professional before use if you are pregnant, breastfeeding, taking medication or being treated for a medical condition.

Still deciding? Ask us on WhatsApp.

Specialists answer routine, dosage and shipping questions.